| payload |
{"created_at":"2026-04-07T23:23:54.391 {"created_at":"2026-04-07T23:23:54.391414+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:45301c53f034bb9d","evidence_event_ids":["evt_91dab5db0956"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","as_of":"2026-04-07T23:23:54.391414+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","company":"Unicycive Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_25960cb33ed9047d","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","content_type":"text/plain","enriched_at":"2026-04-07T23:37:48.739489+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","source_event_id":"evt_91dab5db0956","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"1f1e2a985770511c","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["April 6, 2026","2026-04-06","2026-04-07"],"entities":[{"asset_class":"equity","name":"Unicycive Therapeutics, Inc.","relevance":"high","symbol":"UNCY","type":"issuer"},{"asset_class":"person","name":"Gaurav Aggarwal","relevance":"high","symbol":"","type":"person"},{"asset_class":"governance","name":"Board of Directors","relevance":"medium","symbol":"","type":"governance_body"}],"event_type":"other","information_gaps":["No prior known state is provided in the signal, so the specific 'delta vs prior' cannot be quantified beyond stating this 8-K discloses the resignation.","The filing does not specify whether a replacement director was appointed.","No additional 8-K items (beyond the resignation disclosure) are included in the provided text."],"key_facts":["Form type: 8-K (Current Report).","Date of report / earliest event reported: April 6, 2026.","The company reported that on April 6, 2026, Gaurav Aggarwal resigned from the Board of Directors.","The filing states the resignation was not a result of any disagreement with the company or its management or Board on any matter related to the company\u2019s operations, policies, or practices.","The company expressed gratitude to Dr. Aggarwal for serving on the Unicycive Board of Directors."],"numeric_claims":[],"primary_claim":"On April 6, 2026, director Gaurav Aggarwal resigned from Unicycive Therapeutics, Inc.\u2019s Board of Directors, and the resignation was not due to any disagreement with the company or its management or board.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Unicycive Therapeutics, Inc. filed a Form 8-K on April 6, 2026 to report the resignation of director Gaurav Aggarwal from its Board of Directors. The filing states the resignation was not due to any disagreement with the company or its management/board.","topics":["SEC filing","Form 8-K","director resignation","corporate governance"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Unicycive Therapeutics, Inc. \u00b7 Filed 20260406","ticker":"UNCY","tickers":["UNCY"],"title":"UNCY filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt"}}... |